Showing 3801-3810 of 4164 results for "".
- Sight Sciences Announces New MIGS Data Demonstrating TCOR Using OMNI Surgical System Lowers IOP and Medication Use at 2 Yearshttps://modernod.com/news/sight-sciences-announces-new-migs-data-demonstrating-tcor-using-omni-surgical-system-lowers-iop-and-iop-reducing-medications-at-2-years/2481863/Sight Sciences announced the results of the large scale, comparative real-world clinical outcomes study of patients treated by three leading minimally invasive glaucoma surgery (MIGS) technologies, which were recently presented at the 41st Congress of the European Society of Cataract an
- LumiThera Receives NIH Grant to Support Dry AMD Trialhttps://modernod.com/news/lumithera-receives-nih-grant-to-support-dry-amd-trial/2481855/LumiThera announced it is a recipient of a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH) of up to $2.3 million in funding over 2 years. The NIH/NEI grant supports an open-label human clinical trial in intermediate dry
- Ocugen Announces Positive Update from the Phase 1/2 Trial of OCU400, a Gene Therapy Candidate for the Treatment of RP and LCAhttps://modernod.com/news/ocugen-announces-positive-update-from-the-phase-12-trial-of-ocu400-a-gene-therapy-candidate-for-the-treatment-of-rp-and-lca/2481836/Ocugen announced a clinical study update for retinitis pigmentosa (RP) participants treated in the phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations, and Leber congenital amaurosis (LCA) with mutation(s) in the CE
- Iveric Bio Announces 24-Month Topline Results from Phase 3 Study of Izervay for Geographic Atrophyhttps://modernod.com/news/iveric-bio-announces-24-month-topline-results-from-phase-3-study-of-izervay-for-geographic-atrophy/2481834/Astellas Pharma, the parent company of Iveric Bio, announced positive 24-month topline results from the phase 3 GATHER2 clinical trial evaluating the efficacy and safety of Izervay (avacincaptad pegol intravitreal solution), a recently approved complement C5 inhibitor for the treatment of ge
- Ciliatech Presents Preliminary 1-Year Study Results on Treating Open and Narrow Angle Glaucoma with CIDhttps://modernod.com/news/ciliatech-presents-preliminary-1-year-study-results-on-treating-open-and-narrow-angle-glaucoma-with-cid/2481814/Ciliatech announced it will present at the Ophthalmology Futures Symposium the preliminary results of a 1-year study of its clinical trial, SAFARI III, involving both open and narrow angle glaucoma patients. Preliminary outcomes show an excellent performance and safety profile, wit
- Rayner Unveils Enhancements to Digital Platforms at ESCRS 2023https://modernod.com/news/rayner-unveils-enhancements-to-digital-platforms-at-escrs-2023/2481808/Rayner has announced a series of updates to its digital platforms, RayPRO and Peer2Peer, designed to redefine patient-reported outcome measures (PROMs) and elevate clinical ophthalmic education. Attendees of the ESCRS 2023 congress are invited to explore these advancements at Booth B303
- Amber Ophthalmics Announces First Patient Enrolled in Phase 2/3 Trial Evaluating Nexagon for the Treatment of PCEDhttps://modernod.com/news/amber-ophthalmics-announces-first-patient-enrolled-in-phase-23-trial-evaluating-nexagon-for-the-treatment-of-pced/2481785/Amber Ophthalmics announced that Mark S. Gorovoy, MD, has enrolled the first patient in the AMB-01-006 (NEXPEDE-1), a randomized, double-masked, vehicle-controlled phase 2/3 clinical trial designed to evaluate two concentrations of Nexagon (lufepirsen ophthalmic gel) for
- Skyline Therapeutics’ Gene Therapy Candidate for Wet AMD Receives IND Clearancehttps://modernod.com/news/skyline-therapeutics-gene-therapy-candidate-for-namd-receives-ind-clearance/2481758/Skyline Therapeutics announced that the FDA has cleared the company’s investigational new drug (IND) application for a phase 1/2a clinical trial of SKG0106, a one-time intravitreally delivered adeno-associated virus (AAV) gene therapy for the treatment of wet age-related macular degene
- Okyo Pharma’s OK-101 Will Be Evaluated to Treat Neuropathic Corneal Pain in Study at Tuftshttps://modernod.com/news/okyo-pharmas-ok-101-will-be-evaluated-to-treat-neuropathic-corneal-pain-in-study-at-tufts/2481753/Okyo Pharma, which is developing OK-101 to treat the symptoms of dry-eye disease (DED), announced an agreement with Tufts Medical Center in Boston to conduct a 40-patient, open-label, clinical trial evaluating the efficacy and safety of OK-101 in patients with neuropathic corneal pain (NCP)
- OcuTerra Completes Enrollment in Phase 2 DR:EAM Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathyhttps://modernod.com/news/ocuterra-completes-enrollment-in-phase-2-dream-trial-of-topically-delivered-ott166-in-adults-with-diabetic-retinopathy/2481732/OcuTerra Therapeutics announced full enrollment in the company’s phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating topically delivered OTT166 eye drops in adult patients with moderately severe to severe nonproliferative diabeti